Neumora Therapeutics is trading 5.13% down at $0.67, with no clear catalyst identified for September 25, 2026. - No major company-specific announcement, clinical update, earnings release, or analyst action was identified for that date. - Earlier August coverage highlighted NMRA-215 toxicology progress and a CEO transition. - Major U.S. indexes posted modest gains. Continued biotech-specific weakness or trading pressure may be factors, but available evidence does not establish a direct cause.